Skip to Content

'
Jorge Eduardo Cortes, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine and Internist, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chair, AML Section, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1986 Facultad de Medicina, Universidad Nacional Autónoma de Mexico, Mexico City, Mexico, MD, Medicine
1979 Centro Universitario Mexico, Mexico City, Mexico, BS, Biological Sciences

Postgraduate Training

1/2004 The Essential Training Program for All Medical Staff Leaders, Medical Executive Committee Institute, Rancho Mirage, CA
2003-2004 Faculty Leadership Academy Executive Class, The University of Texas MD Anderson Cancer Center, Houston, TX
1993-1995 Hematology/Oncology Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1991-1992 Hematology Fellowship, University of Texas Health Science Center at Houston, Houston, TX
1990-1992 Hematology Fellowship, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1989-1990 Medical Chief Resident, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1986-1989 Residency in Internal Medicine, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
1985 Mini Residency Course in Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL
1984 Pregraduate Internship, Hospital General de Mexico, SSA, Mexico City, Mexico

Board Certifications

1992 Hematology Board Certification, Mexican Board of Hematology
1989 Internal Medicine Board Certification, Mexican Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2008-2009
Associate Internist and Associate Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 2002-2004
Associate Internist and Associate Professor, Department of Bioimmunotherapy, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1999-2002
Assistant Internist and Assistant Professor, Department of Bioimmunotherapy, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1996-1999
Assistant Internist and Assistant Professor, Department of Leukemia, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1996-1999
Associate Professor, Postgraduate Course of Hematology, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 1995-1996
Chairman, Department of Hematology and Oncology, Instituto Nacional de la Nutricion, Salvador Zubiran, Mexico, 1995-1996
Assistant Professor, Department of Histology, Medical School, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 1981

Administrative Appointments/Responsibilities

Chair, CML Section, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-present
Leukemia Fellowship Program Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-present
Chairman, Department of Hematology / Oncology, Department of Hematology and Oncology, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico, 1995-1996

Other Appointments/Responsibilities

Medical Advisory Board, National CML Society, Houston, TX, 2010-present
Member Executive Committee, International CML Foundation, London, United Kingdom, 2009-present
Member, ASH Journal Committee, American Society of Hematology, Washington, DC, 2009-present
President and Founder, Latin American Leukemia Net, Mexico City, DF, Mexico, 2008-present
Co-Chair, Center for International Blood & Marrow Transplant Research - Chronic Leukemia Working Committee, Milwaukee, WI, 2008-2013
Member, Board of Directors, Leukemia & Lymphoma Society, White Plains, NY, 2007-present
Member, Medical & Science Committee, Leukemia & Lymphoma Society, Houston, TX, 2007-present
Member, Scientific Advisory Board, The Max Foundation, Buenos Aires, Argentina, 2006-present
Abstract Selection Committee, American Society of Hematology, Washington, DC, 2006
Member, Patient Services Committee, Leukemia & Lymphoma Society, White Plains, NY, 2005-present
Member, Advisory Board, TX Gulf Coast Chapter, Leukemia & Lymphoma Society, Houston, TX, 2005-present
Abstract Selection Committee, American Society of Hematology, Washington, DC, 2003

Consultantships

Astra Zeneca, Washington, DC, 2003
Schering Plough, Kenilworth, NJ, 2002-2003
Jensen, Dallas, TX, 2001-2002
Glaxo Smith-Kline, Geneva, Switzerland, 1998-2001
Rhone-Poulenc Rorer, Los Angeles, CA, 1998

Institutional Committee Activities

Chair, IRB5, 2010-present
Member, Council of Committee Chairs, 2009-present
Member, Conflict of Interest Committee, 2009-2012
Chair Elect, Executive Committee of the Medical Staff, 2009-2012
Member, Emergency Center Task Force, 2009
Member, Clinician Educator Task Force, 2007-2008
Chair, Transfusion Committee, 2004-2010
Member, IRB3, 2003-present
Vice Chair, IRB5, 2003-2010
Member, Search Committee ID Chair, 2003-2009
Vice Chair, Clinical Research Committee, 2003-2005
Member, Executive Committee of the Faculty Senate, 2003
Member, Clinical Research Committee, 2002-2003
Member, IRB Subcommittee (to develop policies and procedures for interactions with outside physicians), 2002
Member, Blue Ribbon Committee - Review of Clinical Trials Research, 2002
Chair, Department of Leukemia Protocol Compliance Monitoring Committee, 2001-present
Chair, ICU Committee, 2001-2007
Member, Infection Control Subcommittee, 2001-2005
Member, CTRC Committee, 2001-2002
Member, Clinical Council Sub-Committee for Clinical Research, 2001-2002
Member, Search Committee Chair, Pulmonary Medicine, 2001
Member, Search Committee, Critical Care Faculty, 2001
Member, Search Committee, ID Faculty (Virologist), 2001
Representative for Leukemia Department, Faculty Senate, 2000-2003
Vice Chair, Transfusion Committee, 1999-2004
Vice Chair, ICU Committee, 1999-2001
Member, ATC Task Force, 1999-2000
Member, Fellowship Committee, 1998-2005
Member, Latin American Task Force, 1998-2001

Honors and Awards

2014 2014 Mentor of the Year, Leukemia Fellowship Program
2013-present Member National Academy of Medicine, Mexico
2013 2013 Best Doctors in America
2013 America's Top Doctors, Castle Connolly Medical LTD.
2013 Castle Connolly Top Doctors, Castle Connolly Medical Ltd
2013 Emil J Freireich Award for Clinical Research, UT MD Anderson Cancer Center
2013 Gerald P. Bodey Award for Excellence in Education, UT MD Anderson Cancer Center
2013 Julie and Ben Rogers Award for Excellence in the Area of Research, The University of Texas MD Anderson Cancer Center
2012 2012 Texas Super Doctors, Texas Monthly
2012 2012 Outstanding Patient Educators at MDACC, Outstanding Patient Educator Selection Committee and Patient Education Office
2012 Third place Poster Session Award, Hematologic Maligancnies 2012 VIII International Conference, Houston Tx
2012 Top 1% of Physicians, US News and World Report
2012 Trainee Excellence Award, MD Anderson Alumni & Faculty Association
2011-2012 Best Doctors in America Best Doctors, Medical Oncology and Hematology
2011 March Faculty Educator, UT MD Anderson Cancer Center
2011 Professor David Galton Lecture,, Imperial College of London Hammersmith Hospital, London, UK
2010 Irwin H. Krakoff Award for Excellence in Clinical Research, Division of Cancer Medicine
2010 Irwin H. Krakoff Award for Excellence in Clinical Research Awarded, Fifth Annual Division of Cancer Medicine Faculty Achievement and Recognition Awards Program
2010 JCO Top-Cited Authors, Journal of Clinical Oncology
2008-2013 Elected to 5-year term as Chair Chronic Leukemia Working Committee of the Center for International Blood & Marrow Transplant Research, (CIBMTR)
2008 Establishment of the "Jorge Cortes Lecture", Annual Meeting of the Agrupacion Mexicana Para el Estudio de la Hematologia (AMEH)
2008 Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine 3rd Annual Faculty Recognition and Awards Program
2007 Service to Mankind Award, The Leukemia & Lymphoma Society
2007 The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, UT MD Anderson Cancer Center
2006 Exceptional Leadership and Support as Mentor, UT MD Anderson Cancer Center
2006 The Dr. John J. Kenny Award, The Leukemia & Lymphoma Society
2005 Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology, Celgene
2003 Faculty Scholar Award, UT MD Anderson Cancer Center
2002 Who's Who, Kingston's National Registry
2000 Faculty Excellence Award, UT MD Anderson Cancer Center
2000 Scholar in Clinical Research, The Leukemia & Lymphoma Society (formerly Leukemia Society of America)
1998-1999 Teacher of the Year, Medical Oncology, UT MD Anderson Cancer Center
1995 Aida Weiss Award, 1st Place Scientific Research Protocols Aida Weiss Foundation, and Programa Universitario de Investigacion en Salud, UNAM
1995 Merit Award, American Society of Clinical Oncology
1995 UPJohn "Outstanding Research Award", UT MD Anderson Cancer Center
1994 Clinical Fellows Research Award, UT MD Anderson Cancer Center
1994 Travel Award, American Society of Hematology
1986 First Place Award and Gabino Barreda Medal (for the highest school average during medical school), Universidad Nacional Autonoma de Mexico

Professional Memberships

Agrupacion Mexicana para el Estudio de la Hematologia, Mexico
Member, 1995-present
American Association for Cancer Research
Member, 1997-present
American Society of Clinical Oncology (ASCO)
Member, 1995-present
American Society of Hematology (ASH)
Member, 1994-present
Ecuatorian Oncology Research Group (GOIE)
Honorary Member, 1996-present
Harris County Medical Society, Houston, TX
Member, 1997-present
Medica Sur Medical Society, Mexico
Member, 1993-present
Medical Society of the Instituto Nacional de la Nutricion Salvador Zubiran, Mexico
Member, 1987-present
Mexican Association of Internal Medicine, Mexico
Member, 1989-present
National Academy of Medicine of Mexico, Mexico
Member, 2012-present
NCI-ASH Hematology Clinical Trials Workshop Steering Committee, Washington, DC
Member, 2009-present
Texas Medical Association, TX
Member, 1997-present
The Max Foundation, WA
Member, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Kantarjian H, Cortes JE. Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia. J Clin Oncol. e-Pub 7/2014. PMID: 25002733.
2. Cortes J, Berliner N, Löwenberg B. Clinical trials have a home in Blood. Blood 123(25):3845-6, 6/2014. PMID: 24948618.
3. Romo CG, Jain P, Cortes JE. Numb chin syndrome by Precursor B acute lymphoblastic leukemia (pre B-ALL). Am J Hematol. e-Pub 5/2014. PMID: 24850438.
4. Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. e-Pub 4/2014. PMID: 24711212.
5. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. e-Pub 4/2014. PMID: 24737502.
6. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age. Blood. e-Pub 3/2014. PMID: 24687088.
7. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 123(9):1309-18, 2/2014. PMID: 24345751.
8. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2/2014. PMCID: PMC3946911.
9. Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. e-Pub 2/2014. PMID: 24501394.
10. Cortes JE, Talpaz M, Kantarjian H. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 370(6):577, 2/2014. PMID: 24499221.
11. DiNardo CD, Cortes JE. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs 23(2):265-72, 2/2014. PMID: 24313331.
12. Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J. Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy. Clin Lymphoma Myeloma Leuk. e-Pub 1/2014. PMID: 24594142.
13. Anzalone CL, Cohen PR, Kurzrock R, Cortes JE. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J 20((1)):2, 2014. PMID: 24456946.
14. Quintás-Cardama A, Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes J. Detection of Dormant Chronic Myeloid Leukemia Clones in the Bone Marrow of Patients in Complete Molecular Remission. Clin Lymphoma Myeloma Leuk 13(6):681-5, 12/2013. PMID: 24060288.
15. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 12/2013. PMCID: PMC3849405.
16. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 12/2013. PMCID: PMC3835390.
17. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk. e-Pub 12/2013. PMID: 24332214.
18. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783-96, 11/2013. PMCID: PMC3886799.
19. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686-8, 11/2013. PMCID: PMC3815167.
20. Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica 98(11):e141-2, 11/2013. PMCID: PMC3815188.
21. Kantarjian HM, O'Brien S, Cortes J. Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval. Clin Lymphoma Myeloma Leuk 13(5):530-3, 10/2013. PMCID: PMC3775965.
22. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status. J Clin Oncol 31(29):3681-7, 10/2013. PMCID: PMC3804291.
23. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 13(5):584-91, 10/2013. PMCID: PMC3775895.
24. Nazha A, Romo CG, Kantarjian H, Cortes J. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica 98(10):e131, 10/2013. PMCID: PMC3789475.
25. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors - single institution experience. Leuk Lymphoma. e-Pub 9/10/2013. PMID: 23927391.
26. Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf 12(5):687-96, 9/2013. PMID: 23560546.
27. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 8/2013. PMID: 23969309.
28. Cortes J. First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choice. Oncology (Williston Park) 27(8):781, 8/2013. PMID: 24133826.
29. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641-7, 8/2013. PMCID: PMC3731927.
30. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(4):477-84, 8/2013. PMCID: PMC3752280.
31. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol 162(4):548-52, 8/2013. PMID: 23691988.
32. Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 98(7):e78-9, 7/2013. PMCID: PMC3696599.
33. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975-2009. Leuk Lymphoma 54(7):1411-7, 7/2013. PMID: 23121646.
34. Cortes JE. A journey searching for a cure for leukemia. Interviewed by Natasha Galukande. Future Oncol 9(6):785-7, 6/2013. PMID: 23718297.
35. Jain P, Kantarjian H, Cortes J. Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. Curr Treat Options Oncol 14(2):127-43, 6/2013. PMID: 23572291.
36. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24):4867-74, 6/2013. PMCID: PMC3743466.
37. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 6/2013. PMID: 23530930.
38. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. Clin Lymphoma Myeloma Leuk 13(3):302-6, 6/2013. e-Pub 1/12/2013. PMID: 23318257.
39. Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 88(5):350-4, 5/2013. PMID: 23468307.
40. Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol 14(4):354-62, 4/2013. PMID: 23453583.
41. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients withadvanced myeloid malignancies. Haematologica 98(2):217-21, 2/2013. PMCID: PMC3561428.
42. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 6(1):79, 2013. PMID: 24283870.
43. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819-22, 12/2012. PMID: 22605576.
44. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075-88, 11/29/2012. PMID: 23190221.
45. Cortes J. Bosutinib in the treatment of chronic myelogenous leukemia. Clin Adv Hematol Oncol 10(11):736-7, 11/2012. PMID: 23271260.
46. Cortes J. CML: the good, the better, and the difficult choices. Blood 120(19):3866-7, 11/2012. PMID: 23144157.
47. Santos FP, Cortes J. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Pharmacother 13(16):2381-95, 11/2012. PMID: 22992064.
48. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. J Clin Oncol 30(28):3486-92, 10/2012. PMID: 22949154.
49. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 120(16):3382-3, 10/2012. PMID: 23086624.
50. Cortes J, Radich J, Mauro MJ. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clin Adv Hematol Oncol 10(10 Suppl 19):1-16, 10/2012. PMID: 23187745.
51. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw 10 Suppl 3:S1-S13, 10/2012. PMID: 23055247.
52. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-Associated Vascular Events. Clin Lymphoma Myeloma Leuk 12(5):337-40, 10/2012. PMID: 22633167.
53. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120(13):2573-80, 9/2012. PMID: 22896000.
54. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 120(7):1390-7, 8/2012. PMID: 22613793.
55. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 7/2012. PMCID: PMC3396674.
56. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118(12):3116-22, 6/2012. PMCID: PMC3370116.
57. Cortes J. Chronic myeloid leukemia: The race is yet to be won. CMAJ 184(8):857-8, 5/2012. PMCID: PMC3348186.
58. Fava C, Kantarjian H, Cortes J. Molecular Resistance: An Early Indicator for Treatment Change? Clin Lymphoma Myeloma Leuk 12(2):79-87, 4/2012. PMID: 22285607.
59. Daver N, Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology 17 Suppl 1:59-62, 4/2012. PMID: 22507781.
60. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 3/2012. PMCID: PMC3311242.
61. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial. Cancer 118(3):848-55, 2/2012. PMID: 21751205.
62. Cortes JE. Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. J Clin Oncol 30(3):223-4, 1/20/2012. e-Pub 12/19/2011. PMID: 22184376.
63. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118(2):418-27, 1/2012. PMID: 21717444.
64. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118(20):5697-700, 11/2011. PMID: 21926354.
65. Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J 17(6):465-76, Nov-Dec, 11/2011. PMCID: PMC3243359.
66. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response? J Clin Oncol 29(32):4260-5, 11/2011. PMCID: PMC3221527.
67. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am 25(5):981-95, 10/2011. PMID: 22054730.
68. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood 118(17):4567-76, 10/2011. PMID: 21865346.
69. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk 11(5):421-6, 10/2011. PMCID: PMC3215673.
70. Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era? Cancer 117(15):3293-304, 8/2011. PMID: 21319142.
71. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29(23):3173-8, 8/2011. PMID: 21747082.
72. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):355-60, 8/2011. PMID: 21816374.
73. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600-6, 5/2011. PMID: 21467546.
74. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117(9):1800-11, 5/2011. PMID: 21509757.
75. Kantarjian H, Cortes J. Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. J Clin Oncol 29(12):1512-6, 4/2011. PMID: 21422414.
76. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 3/2011. PMID: 20960519.
77. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 3/2011. PMID: 20960502.
78. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 117(6):1113-22, 3/2011. PMID: 20960522.
79. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29(5):524-31, 2/2011. PMID: 21220597.
80. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3):572-80, 2/2011. PMID: 20886606.
81. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 117(6):1822-7, 2/2011. PMID: 21030554.
82. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 1/2011. PMID: 20845478.
83. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 1/2011. PMCID: PMC3012766.
84. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 116(23):5074-5, 12/02/2010, 12/2010. PMID: 21127188.
85. Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Cortés JE. Proceedings of the third global workshop on chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10(6):443-51, 12/2010. PMID: 21156461.
86. Cortés JE. Selected US Trials in Adult Leukemia/Myelodysplastic Syndrome - Status, November 2010: Open for Enrollment. Clin Lymphoma Myeloma Leuk 10(6):484-5, 12/2010. PMID: 21156468.
87. Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, Hamerschlak N, Pagnano K, Pasquini R, Meillon L. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer 116(21):4991-5000, 11/2010. PMID: 20665487.
88. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 47(4):344-53, 10/2010. PMID: 20875551.
89. Quintás-Cardama A, Kantarjian H, Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol 47(4):371-80, 10/2010. PMID: 20875554.
90. Cortes J. Towards a cure for chronic myeloid leukemia: are we there yet? Semin Hematol 47(4):299-301, 10/2010. PMID: 20875545.
91. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 12(5):302-13, 9/2010. PMID: 20640942.
92. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303-12, 8/2010. PMID: 20553275.
93. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116(13):3152-9, 7/2010. PMID: 20564631.
94. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 115(26):5428-9, 7/2010. PMID: 20595523.
95. Quintás-Cardama A, Kantarjian H, Cortés JE. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10:S14-9, 6/2010. PMID: 20529803.
96. Jabbour E, Fullmer A, Cortés JE, Kantarjian H. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk 10:S6-S13, 6/2010. PMID: 20529808.
97. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/2010. PMID: 20499401.
98. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 116(2):377-86, 1/2010. PMID: 19924787.
99. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 1/2010. PMCID: PMC2815701.
100. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28(3):424-30, 1/2010. PMID: 20008622.
101. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 1/2010. PMCID: PMC2815702.
102. Quintás-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115(23):5382-93, 12/2009. PMID: 19739234.
103. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. J Clin Oncol 27(28):4754-9, 10/1/2009. e-Pub 8/31/2009. PMID: 19720924.
104. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 Trial. Cancer 115(17):3924-34, 9/2009. PMID: 19536894.
105. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. J Clin Oncol 27(22):3659-63, 8/2009. PMCID: PMC2799063.
106. Cole S, Kantarjian H, Ault P, Cortés JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma 9(4):324-7, 8/2009. PMID: 19717385.
107. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-3, 7/2009. PMID: 19414863.
108. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-90, 6/2009. PMID: 19280591.
109. Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 6/2009. PMID: 19369233.
110. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 84(5):287, 5/2009. PMID: 19306355.
111. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol 84(4):256-257, 4/2009. PMID: 19260121.
112. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 115(7):1381-1394, 4/2009. PMID: 19195046.
113. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122-31, 4/2009. PMID: 19337198.
114. Fava C, Cortes J. Optimizing first-line therapy for patients with chronic myeloid leukemia. Semin Hematol 46(2 Suppl 3):S5-10, 4/2009. PMID: 19621543.
115. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-60, 3/2009. PMID: 19060245.
116. Cortes J, De Keersmaecker K. T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. Leuk Lymphoma 50(3):321-2, 3/2009. PMID: 19294558.
117. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368-73, 1/2009. PMID: 19118067.
118. Cortés JE. Chronic myeloid leukemia: where do we go now? Clin Lymphoma Myeloma 9 Suppl 4:S374-5, 2009. PMID: 20007105.
119. Quintás-Cardama A, Cortés JE. The next generation of therapies for chronic myeloid leukemia. Clin Lymphoma Myeloma 9 Suppl 4:S395-403, 2009. PMID: 20007109.
120. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42, 12/2008. PMID: 18818391.
121. Quintás-Cardama A, Cortes J. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol 4(5):611-21, 10/2008. PMID: 18922118.
122. Quintas-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 113(8):1619-30, 9/2008. PMID: 18827185.
123. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-8, 8/2008. PMID: 18492956.
124. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49(7):1399-402, 7/2008. PMID: 18452066.
125. Quintás-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14(14):4392-9, 7/2008. PMID: 18628453.
126. Quintás-Cardama A, Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs 17(7):1039-50, 7/2008. PMID: 18549340.
127. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/2008. PMID: 18085610.
128. Cortes JE. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol 26(20):3308-9, 2008. PMID: 18519950.
129. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111(4):1774-80, 2008. PMID: 18055868.
130. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs 16(3):381-92, 3/2007. PMID: 17302532.
131. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13(4):1089-97, 2007. PMID: 17317816.
132. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913-23, 12/2006. PMID: 17179059.
133. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107(2):480-2, 1/2006. PMID: 16195326.
134. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-73, 2006. PMID: 16855631.
135. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108(8):2811-3, 2006. PMID: 16809614.
136. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol 83(4):289-93, 2006. PMID: 16757426.
137. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol 13(2):79-86, 2006. PMID: 16456373.
138. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24(7):1204-8, 2006. PMID: 16446320.
139. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306-15, 2006. PMID: 16463391.
140. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108(6):1835-40, 2006. PMID: 16709931.
141. Alvarez RH, Kantarjian HM, Cortes J. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107(8):1918-29, 2006.
142. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105(6):2281-6, 2005. PMID: 15572595.
143. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 2005. PMID: 15867244.
144. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 23(26):6316-24, 2005. PMID: 16155014.
145. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-12, 2005. PMID: 15728224.
146. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104(4):777-80, 2005. PMID: 15971197.
147. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 2005. PMID: 15830345.
148. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46(7):993-7, 2005. PMID: 16019549.
149. Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 76:2393-417, 1995. PMID: 8625065.
150. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 9:115-7, 1995. PMID: 7845005.
151. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 13:2643-55, 1995. PMID: 7595719.
152. Cortes J, Kantarjian H. Leukemia in the elderly. Cancer Bull 47:203-211, 1995.
153. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86:2091-7, 1995. PMID: 7662956.
154. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 8:2174-8, 1994. PMID: 7808007.
155. Cortes Franco JE, Gamba Ayala G, Aguilar Salinas CA, Manfrini Madrid F, Gonzalez Chon O, Castorena G. In hospital transport of critically ill patients. Rev Invest Clin 43:323-8, 1991. PMID: 1798866.
Other Articles
1. Cortes, J. Emerging Therapies for Patients with TKI- Resistant Chronic Myelogenous Leukemia: Clinical Trial Data. Clinical Advances in Hematology & Oncology 10(10):7-9, 10/2012.

Abstracts

1. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 2006. PMID: 16342165.
2. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81(7):973-88, 2006. PMID: 16835977.
3. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107(7):1525-9, 2006. PMID: 16955510.
4. Quintas-Cardama A, Kantarjian H, Cortes J. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol 2(6):655-65, 12/2006. PMID: 17155893.
5. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480-2, 2006. PMID: 16195326.
6. Quintas-Cardama A, Cortes J. Kinase inhibitors in chronic myelogenous leukemia. Clin Adv Hematol Oncol 4(5):365-74, 2006. PMID: 16728945.
7. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109(2):497-9, 2007. PMID: 16990591.
8. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 1/2007. PMID: 17154172.
9. Atallah E, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol 14(2):138-44, 2007. PMID: 17255791.
10. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-9, 2007. PMID: 17325887.
11. Wetzler M, Hellman A, Lipton J, Roy L, Jones D, Schenk T, Hochhaus A, Benichou A, Kantarjian H, Cortes J. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) paients resistant or intolerant to two or more tyrosines kinase inhibitors (TKI's): Data from an ongoing phase II trial. Journal of Clinical Oncology 27(15s):362s (#7027), 5/2009.
12. Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas D.A, Verstovsek S, Rios M, Cortes J. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL, fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance. Journal of Clinical Oncology 27(15s):363s (#7030), 5/2009.
13. Cortes J.E, Khoury H.J, Corm S, Nicolini F. Schenk T, Jones D, Hochhaus A, Craig A.R, Humphriss E, Kantarjian H. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T3151 mutation: Data from an ongoing phase IVII trial. Journal of Clinical Oncology 27(15s):358s (#7008), 5/2009.
14. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Verstovsek S, Wierda W, Shan J, Cortes J. Prognostic Impact of deletions of derivative chromosome 9 on patients (PTS) with chronic myelogenous leukemia (CML) in chronic phase treated iwth Nilotinib or dasatinib. Blood 112(11):734 (#2110), 11/2009.
15. Tong W, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Wierda W.G, Kornblau S, Borthakur G, Garcia-Manero G, Burton E, Rios M.B, Cortes J. Imatinib frontline therapy is safe and effective in patients with chronic myeloid leukemia (CML) with liver and/or renal dysfunction. Blood 112(11):741 (#2126), 11/2008.
16. Cortés JE. Chronic myeloid leukemia: where do we go now?. Clin Lymphoma Myeloma 9 Suppl 4:S374-5, 2009. PMID: 20007105.

Book Chapters

1. Cortes JE Kantarjian H , Wierda W. Chronic Myeloid Leukemia. In: Conn's Current Therapy, 456-463, 2009.

Last updated: 7/28/2014